date,title,source
Oct-29-18,"CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018",PR Newswire
Oct-31-18,"Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline",PR Newswire
Nov-08-18,CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting,PR Newswire
Nov-09-18,Bet on Rising P/E Investing With These 5 Top-Ranked Stocks,Zacks
Nov-12-18,"Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems",Zacks
Nov-15-18,Edited Transcript of CYTR earnings conference call or presentation 2-Nov-18 3:00pm GMT,Thomson Reuters StreetEvents
Nov-16-18,Edited Transcript of CYTR earnings conference call or presentation 2-Nov-18 3:00pm GMT,Thomson Reuters StreetEvents
Nov-23-18,"Report: Exploring Fundamental Drivers Behind Graphic Packaging Holding, QEP Resources, Inogen, CytRx, Voyager Therapeutics, and Daily Journal Corp. (S.C.)  New Horizons, Emerging Trends, and Upcoming Developments",GlobeNewswire
Nov-28-18,CytRx Corporation to Present at the 11th Annual LD Micro Main Event,PR Newswire
Dec-21-18,CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR Drug Candidates and Accompanying Companion Diagnostic,PR Newswire
Jan-14-19,CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial,PR Newswire
Feb-06-19,CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S,PR Newswire
Feb-11-19,CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy,PR Newswire
Feb-13-19,CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR Technology Targeting Delivery Directly to the Tumor,PR Newswire
Mar-12-19,"CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems",PR Newswire
Mar-29-19,CytRx Corporation Reports 2018 Financial Results,PR Newswire
